A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Voclosporin (LUPKYNIS)

Calcineurin Inhibitor Immunosuppressant class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2021-01-22
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$41.3M in CY2024 Part D spend3K claims · 647 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
22 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Voclosporin used for?

Voclosporin is a Calcineurin Inhibitor Immunosuppressant medication tracked in Medicare Part D.

Is there a generic for Voclosporin?

No. Voclosporin is brand-only with no generic equivalents currently in market.

How much does my plan pay for Voclosporin?

NADAC pricing data not currently available for this drug.

Is Voclosporin on the FDA shortage list?

No. Voclosporin is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Calcineurin Inhibitor Immunosuppressant4 alternatives in D1
01
Cyclosporine
Brand: CEQUA
$0.310Lowest NADAC
15Generic mfrs
$2.51BCY24 Part D spend
Compare →
02
Cyclosporine Ophthalmic Solution
Brand: VEVYE
$368.54Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Pimecrolimus
Calcineurin Inhibitor Immunosuppressant
$2.69Lowest NADAC
2Generic mfrs
$27.2MCY24 Part D spend
Compare →
04
Tacrolimus
Brand: Envarsus
$0.154Lowest NADAC
15Generic mfrs
$156.6MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.